ATyr Financial Statements From 2010 to 2025

ATYR Stock   5.25  0.91  14.77%   
ATyr Pharma,'s financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ATyr Pharma,'s valuation are provided below:
Gross Profit
-52.8 M
Market Capitalization
548.3 M
Enterprise Value Revenue
132.1671
Earnings Share
(0.80)
There are over one hundred nineteen available fundamental signals for aTyr Pharma,, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate ATyr Pharma,'s prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 07/30/2025, Market Cap is likely to grow to about 282.3 M. Also, Enterprise Value is likely to grow to about 284.6 M

ATyr Pharma, Total Revenue

223,250

Check ATyr Pharma, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ATyr Pharma,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 567.6 K or Gross Profit of 246.8 K, as well as many indicators such as Price To Sales Ratio of 1.2 K, Dividend Yield of 0.0 or PTB Ratio of 4.03. ATyr financial statements analysis is a perfect complement when working with ATyr Pharma, Valuation or Volatility modules.
  
Build AI portfolio with ATyr Stock
Check out the analysis of ATyr Pharma, Correlation against competitors.
To learn how to invest in ATyr Stock, please use our How to Invest in ATyr Pharma, guide.

ATyr Pharma, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets78.2 M96.8 M63.6 M
Slightly volatile
Short and Long Term Debt Total10.8 M13.3 M9.2 M
Slightly volatile
Other Current Liabilities5.6 M9.4 M4.7 M
Slightly volatile
Total Current Liabilities11.1 M15 M9.3 M
Slightly volatile
Property Plant And Equipment Net12.5 M11.9 M4.9 M
Slightly volatile
Current Deferred Revenue0.860.9119.3 K
Slightly volatile
Accounts Payable2.3 M4.3 M1.9 M
Slightly volatile
Cash16.1 M11.1 M17.8 M
Very volatile
Non Current Assets Total9.2 M14.9 M7.7 M
Slightly volatile
Non Currrent Assets Other62.7 K66 K318.1 K
Slightly volatile
Cash And Short Term Investments64.8 M72.1 M52.4 M
Slightly volatile
Common Stock Shares Outstanding78 M74.3 M24.4 M
Slightly volatile
Liabilities And Stockholders Equity78.2 M96.8 M63.6 M
Slightly volatile
Non Current Liabilities Total17.4 M12 M19.4 M
Pretty Stable
Other Current Assets8.5 M8.1 M2.6 M
Slightly volatile
Total Liabilities25.4 M27 M28.5 M
Pretty Stable
Total Current Assets69 M82 M55.8 M
Slightly volatile
Short Term Debt2.3 M1.3 M2.6 M
Very volatile
Common Stock88.2 K84 K27.3 K
Slightly volatile
Other Stockholder Equity375.4 M602 M282.7 M
Slightly volatile
Short Term Investments50.4 M61.1 M35.1 M
Slightly volatile
Short and Long Term DebtM7.9 M8.6 M
Slightly volatile
Net Receivables1.6 M1.7 M2.5 M
Pretty Stable
Capital Lease Obligations9.6 M13.3 M4.7 M
Slightly volatile
Net Invested Capital82.1 M70 M48.2 M
Slightly volatile
Property Plant And Equipment Gross15.5 M16.4 M11.4 M
Slightly volatile
Capital Stock47.3 K84 K23.3 K
Slightly volatile
Net Working Capital78.7 M67 M45.8 M
Slightly volatile
Other Assets0.80.90.9813
Slightly volatile

ATyr Pharma, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.3 M1.5 M1.1 M
Slightly volatile
Interest Expense567.6 K956.8 K694 K
Slightly volatile
Other Operating Expenses42.9 M68.1 M35.9 M
Slightly volatile
Research Development30.6 M54.4 M25.5 M
Slightly volatile
Cost Of Revenue1.5 M1.5 M2.9 M
Pretty Stable
Total Operating Expenses42.1 M68.1 M35.3 M
Slightly volatile
Selling General Administrative11.7 M13.8 M9.5 M
Slightly volatile
Selling And Marketing Expenses1.8 M3.2 M1.6 M
Slightly volatile
Reconciled Depreciation1.9 M1.5 M1.4 M
Slightly volatile

ATyr Pharma, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation1.3 M1.5 M1.1 M
Slightly volatile
Capital Expenditures61.8 K65 K769.5 K
Pretty Stable
End Period Cash Flow16.5 M14 M18.2 M
Very volatile
Stock Based Compensation2.4 MM1.7 M
Slightly volatile
Begin Period Cash Flow17.1 M26 M17.8 M
Pretty Stable
Issuance Of Capital Stock39.6 M40.3 M33.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.2 K1.1 K172
Slightly volatile
Days Sales Outstanding2.8 K2.7 K604
Slightly volatile
Stock Based Compensation To Revenue13.3612.71914.7657
Slightly volatile
Capex To Depreciation0.04010.04220.7215
Slightly volatile
EV To Sales1.2 K1.2 K176
Slightly volatile
Payables Turnover0.340.35622.3185
Pretty Stable
Sales General And Administrative To Revenue61.5658.625523.8828
Slightly volatile
Research And Ddevelopement To Revenue24323158.5568
Slightly volatile
Capex To Revenue0.260.27660.9178
Slightly volatile
Cash Per Share0.920.971277.7085
Slightly volatile
Days Payables Outstanding620K639
Very volatile
Income Quality0.71.07960.8333
Slightly volatile
Current Ratio5.225.47565.792
Slightly volatile
Receivables Turnover0.130.13543.6611
Slightly volatile
Capex Per Share8.0E-49.0E-41.4821
Slightly volatile
Revenue Per Share0.0030.00320.1964
Pretty Stable
Interest Debt Per Share0.170.178925.3133
Slightly volatile
Debt To Assets0.230.13720.2616
Slightly volatile
Operating Cycle2.8 K2.7 K604
Slightly volatile
Days Of Payables Outstanding620K639
Very volatile
Ebt Per Ebit1.10.94271.0101
Pretty Stable
Effective Tax Rate1.0E-41.0E-40.0017
Very volatile
Quick Ratio5.225.47565.792
Slightly volatile
Net Income Per E B T1.161.01.0777
Slightly volatile
Cash Ratio0.70.73862.0025
Slightly volatile
Days Of Sales Outstanding2.8 K2.7 K604
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.821.00091.0185
Slightly volatile
Fixed Asset Turnover0.01880.01980.3999
Pretty Stable
Debt Ratio0.230.13720.2616
Slightly volatile
Price Sales Ratio1.2 K1.1 K172
Slightly volatile
Asset Turnover0.00230.00240.0382
Pretty Stable

ATyr Pharma, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap282.3 M268.8 M48.2 M
Slightly volatile

ATyr Fundamental Market Drivers

Cash And Short Term Investments72.1 M

About ATyr Pharma, Financial Statements

ATyr Pharma, shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ATyr Pharma, investors may analyze each financial statement separately, they are all interrelated. The changes in ATyr Pharma,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on ATyr Pharma,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue 0.90  0.86 
Cost Of Revenue1.5 M1.5 M
Total Revenue235 K223.2 K
Stock Based Compensation To Revenue 12.72  13.36 
Sales General And Administrative To Revenue 58.63  61.56 
Research And Ddevelopement To Revenue 231.37  242.94 
Capex To Revenue 0.28  0.26 
Ebit Per Revenue(289.00)(274.55)

Pair Trading with ATyr Pharma,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ATyr Pharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ATyr Pharma, will appreciate offsetting losses from the drop in the long position's value.

Moving together with ATyr Stock

  0.76A Agilent Technologies Earnings Call TomorrowPairCorr
  0.61JNJ Johnson JohnsonPairCorr

Moving against ATyr Stock

  0.83ERNA Eterna TherapeuticsPairCorr
  0.75CLOV Clover Health Investments Earnings Call This WeekPairCorr
  0.68TELO Telomir Pharmaceuticals,PairCorr
  0.64MOLN Molecular PartnersPairCorr
  0.57TOVX Theriva BiologicsPairCorr
The ability to find closely correlated positions to ATyr Pharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ATyr Pharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ATyr Pharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling aTyr Pharma, to buy it.
The correlation of ATyr Pharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ATyr Pharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if aTyr Pharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ATyr Pharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for ATyr Stock Analysis

When running ATyr Pharma,'s price analysis, check to measure ATyr Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma, is operating at the current time. Most of ATyr Pharma,'s value examination focuses on studying past and present price action to predict the probability of ATyr Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma,'s price. Additionally, you may evaluate how the addition of ATyr Pharma, to your portfolios can decrease your overall portfolio volatility.